{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:50:58Z","timestamp":1790596258546,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Safety Pharmacology Society"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.vascn.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:40:34Z","timestamp":1464914434000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Safety pharmacology investigations on the nervous system: An industry survey"],"prefix":"10.1016","volume":"81","author":[{"given":"Simon","family":"Authier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Arezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Delatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Jeanne","family":"Kallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Markgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2016.06.001_bb0005","first-page":"373","article-title":"Effects of lithium on peripheral neuropathy induced by vincristine in rats","volume":"50","author":"Alimoradi","year":"2012","journal-title":"Acta Medica Iranica"},{"key":"10.1016\/j.vascn.2016.06.001_bb0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","article-title":"2015 Alzheimer's disease facts and figures","volume":"11","author":"Alzheimer's Association","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.vascn.2016.06.001_bb0015","author":"Anon"},{"issue":"1","key":"10.1016\/j.vascn.2016.06.001_bb0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0192623310390231","article-title":"Correlation and dissociation of electrophysiology and histopathology in the assessment of toxic neuropathy","volume":"39","author":"Arezzo","year":"2011","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2354.2006.00718.x","article-title":"Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy","volume":"16","author":"Argyriou","year":"2007","journal-title":"European Journal of Cancer Care"},{"key":"10.1016\/j.vascn.2016.06.001_bb0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: Phase II and phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2016.06.001_bb0035","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4088\/JCP.v60n1005","article-title":"Zolpidem for persistent insomnia in SSRI-treated depressed patients","volume":"60","author":"Asnis","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.vascn.2016.06.001_bb0040","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0376-8716(03)00099-1","article-title":"Principles of drug abuse liability assessment in laboratory animals","volume":"70","author":"Ator","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.vascn.2016.06.001_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.vascn.2008.12.003","article-title":"Video-electroencephalography in conscious non-human primate using radiotelemetry and computerized analysis: Refinement of a safety pharmacology model","volume":"60","author":"Authier","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.vascn.2010.06.005","article-title":"Arrhythmogenic liability screening in cardiovascular safety pharmacology: Commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies","volume":"62","author":"Authier","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vascn.2012.08.010","article-title":"Functional observation battery in nonhuman primates with continuous intracerebral infusion","volume":"66","author":"Authier","year":"2012","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vascn.2013.05.002","article-title":"Safety pharmacology investigations in toxicology studies: An industry survey","volume":"68","author":"Authier","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vascn.2014.05.003","article-title":"Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in cynomolgus monkeys","volume":"70","author":"Authier","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/faat.1997.2357","article-title":"Evaluation of effect profiles: Functional Observational Battery outcomes","volume":"40","author":"Baird","year":"1997","journal-title":"Fundamental and Applied Toxicology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vascn.2014.07.005","article-title":"Telemetry video-electroencephalography (EEG) in rats, dogs and non-human primates: Methods in follow-up safety pharmacology seizure liability assessments","volume":"70","author":"Bassett","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0080","author":"BCC Research"},{"issue":"7","key":"10.1016\/j.vascn.2016.06.001_bb0085","first-page":"975","article-title":"The pharmacogenomics of vincristine-induced neuropathy: On pins and needles","volume":"1","author":"Berg","year":"2015","journal-title":"Journal of the American Medical Association Oncology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0090","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-05-2177","article-title":"Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity","volume":"12","author":"Bianchi","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.vascn.2016.06.001_bb0095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nbd.2015.07.006","article-title":"Paclitaxel inhibits mRNA transport in axons","volume":"82","author":"Bobylev","year":"2015","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.vascn.2016.06.001_bb0100","first-page":"137","article-title":"Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat","volume":"18","author":"Cavaletti","year":"1997","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1023\/A:1008231925889","article-title":"Carboplatin toxic effects on the peripheral nervous system of the rat","volume":"9","author":"Cavaletti","year":"1998","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.DMPK-12-RG-004","article-title":"Risk of insomnia attributable to \u03b2-blockers in elderly patients with newly diagnosed hypertension","volume":"28","author":"Chang","year":"2013","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"Suppl 1","key":"10.1016\/j.vascn.2016.06.001_bb9000","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.4103\/0976-500X.120975","article-title":"Corticosteroid-related central nervous system side effects","volume":"4","author":"Ciriaco","year":"2013","journal-title":"Journal of Pharmacology & Pharmacotherapeutics"},{"key":"10.1016\/j.vascn.2016.06.001_bb0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/00002512-200623060-00005","article-title":"Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease","volume":"23","author":"Cooke","year":"2006","journal-title":"Drugs & Aging"},{"key":"10.1016\/j.vascn.2016.06.001_bb0125","doi-asserted-by":"crossref","first-page":"e00106","DOI":"10.1002\/prp2.106","article-title":"Revision of instructions to authors for pharmacology research and perspectives: Enhancing the quality and transparency of published work","author":"Curtis","year":"2015","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.vascn.2016.06.001_bb0130","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: New guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0135","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12028-013-9935-x","article-title":"The epidemiology of status epilepticus in the United States","volume":"20","author":"Dham","year":"2014","journal-title":"Neurocritical Care"},{"key":"10.1016\/j.vascn.2016.06.001_bb0140","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.drudis.2009.06.003","article-title":"Approaches to seizure risk assessment in preclinical drug discovery","volume":"14","author":"Easter","year":"2009","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.vascn.2016.06.001_bb0145","first-page":"A42","article-title":"Incident epilepsy\/seizure disorder in US nursing homes by predisposing conditions, 2003\u20132007","volume":"74","author":"Elberly","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0150","series-title":"Guideline on the non-clinical investigation of the dependence potential of medicinal products. EMEA\/CHMP\/SWP\/94227\/2004","author":"European Medicines Agency (EMEA)","year":"2006"},{"key":"10.1016\/j.vascn.2016.06.001_bb0155","series-title":"Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for pediatric indications. EMEA\/CHMP\/SWP\/169215\/2005","author":"European Medicines Agency (EMEA)","year":"2008"},{"key":"10.1016\/j.vascn.2016.06.001_bb0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.vascn.2013.04.008","article-title":"A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions","volume":"68","author":"Ewart","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-662-46943-9_4","article-title":"CNS adverse effects: From functional observation battery\/Irwin tests to electrophysiology","volume":"229","author":"Fonck","year":"2015","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0170","series-title":"Nonclinical safety evaluation of pediatric drug products","author":"Food and Drug Administration (FDA) Guidance Document","year":"2006"},{"key":"10.1016\/j.vascn.2016.06.001_bb0175","series-title":"Assessment of abuse potential of drugs","author":"Food and Drug Administration (FDA) Guidance for Industry","year":"2010"},{"issue":"8","key":"10.1016\/j.vascn.2016.06.001_bb0180","doi-asserted-by":"crossref","first-page":"e105601","DOI":"10.1371\/journal.pone.0105601","article-title":"Identification and validation of suitable housekeeping genes for normalizing quantitative real-time PCR assays in injured peripheral nerves","volume":"9","author":"Gambarotta","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.vascn.2016.06.001_bb0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1528-1157.1970.tb03871.x","article-title":"Clinical and electroencephalographical classification of epileptic seizures","volume":"11","author":"Gastaut","year":"1970","journal-title":"Epilepsia"},{"key":"10.1016\/j.vascn.2016.06.001_bb0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.vascn.2008.05.002","article-title":"A functional observational battery in non-human primates for regulatory-required neurobehavioral assessments","volume":"58","author":"Gauvin","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"15","key":"10.1016\/j.vascn.2016.06.001_bb0195","first-page":"00050","article-title":"Abuse liability assessment of hydrocodone under current draft regulatory guidelines","author":"Gauvin","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.vascn.2008.05.024","article-title":"Neurobehavioural assessment in pre-clinical species: Rodents, dogs, mini-pigs and monkeys","volume":"58","author":"Giarola","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neuroscience"},{"key":"10.1016\/j.vascn.2016.06.001_bb0210","first-page":"1","article-title":"Prescription drug use continues to increase: U.S. prescription drug data for 2007\u20132008","volume":"42","author":"Gu","year":"2010","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.vascn.2016.06.001_bb0215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935\u20131984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.vascn.2016.06.001_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.vascn.2008.06.001","article-title":"Safety pharmacology assessment of central nervous system function in juvenile and adult rats: Effects of pharmacological reference compounds","volume":"58","author":"Himmel","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0230","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00213-013-3027-7","article-title":"Assessment of the abuse liability of ABT-288, a novel histamine H3 receptor antagonist","volume":"228","author":"Hudzik","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"Comprehensive observational assessment: A systematic quantitative procedure for assessing the behavioural and physiologic state of the mouse","volume":"13","author":"Irwin","year":"1968","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0240","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-3-662-46943-9_5","article-title":"Preclinical abuse potential assessment","volume":"229","author":"Kallman","year":"2015","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2015.06.003","article-title":"Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report","volume":"76","author":"Klein","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0250","first-page":"120","article-title":"Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy","volume":"109","author":"Kocer","year":"2009","journal-title":"Acta Neurologica"},{"key":"10.1016\/j.vascn.2016.06.001_bb0255","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2131\/jts.39.579","article-title":"Establishment of a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish","volume":"39","author":"Koseki","year":"2014","journal-title":"Journal of Toxicological Sciences"},{"issue":"15","key":"10.1016\/j.vascn.2016.06.001_bb0260","first-page":"00154","article-title":"MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy","author":"Li","year":"2015","journal-title":"Brain Behavior Immunology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vascn.2008.07.001","article-title":"Benchmarking safety pharmacology regulatory packages and best practice","volume":"58","author":"Lindgren","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2016.06.001_bb0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0920-1211(91)90062-K","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models","volume":"8","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.vascn.2016.06.001_bb0275","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1056\/NEJM199804023381407","article-title":"Status epilepticus","volume":"338","author":"Lowenstein","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vascn.2016.06.001_bb0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.vascn.2010.06.001","article-title":"Comparison of methods for analysis of functional observation battery (FOB) data","volume":"62","author":"Markgraf","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0285","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrd3226","article-title":"Pain market","volume":"9","author":"Melnikova","year":"2010","journal-title":"Nature Reviews Drug Discovery"},{"issue":"15","key":"10.1016\/j.vascn.2016.06.001_bb0290","first-page":"00039","article-title":"Assessment of seizure risk in pre-clinical studies: Strengths and limitations of the electroencephalogram (EEG)","author":"Metea","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0295","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/17460441.2013.768984","article-title":"How can attrition rates be reduced in cancer drug discovery?","volume":"8","author":"Moreno","year":"2013","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"2","key":"10.1016\/j.vascn.2016.06.001_bb0300","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.vascn.2007.03.007","article-title":"An optimized methodology for the neurobehavioural assessment in rodents","volume":"56","author":"Moscardo","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0305","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.vascn.2009.05.005","article-title":"An optimized neurobehavioural observation battery integrated with the assessment of cardiovascular function in the beagle dog","volume":"60","author":"Moscardo","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vascn.2010.06.006","article-title":"An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey","volume":"62","author":"Moscardo","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000402387","article-title":"Propranolol and newer antihypertensive drugs in the management of hypertension","volume":"26","author":"Moser","year":"1979","journal-title":"Advances in Cardiology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0320","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.vascn.2010.09.004","article-title":"Current approaches and issues in non-clinical evaluation of abuse and dependence","volume":"63","author":"Moser","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0325","first-page":"373","article-title":"Cancer market hits $100 billion","volume":"14","author":"Mullard","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1016\/j.vascn.2016.06.001_bb0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2014.04.096","article-title":"2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: Statistics from World Health Organisation and United Nations","volume":"174","author":"Nowbar","year":"2014","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0335","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2012.05.001","article-title":"Translational CNS medicines research","volume":"17","author":"Palmer","year":"2012","journal-title":"Drug Discovery Today"},{"issue":"2","key":"10.1016\/j.vascn.2016.06.001_bb0340","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0160-5402(85)90057-9","article-title":"A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat","volume":"13","author":"Pollack","year":"1985","journal-title":"Journal of Pharmacological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0345","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1472-8206.2002.00061.x","article-title":"New perspectives in CNS safety pharmacology","volume":"16","author":"Porsolt","year":"2002","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0350","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/bjp.2008.280","article-title":"Principles of safety pharmacology","volume":"154","author":"Pugsley","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0355","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.vascn.2009.07.001","article-title":"Beyond the safety assessment of drug-mediated changes in the QT interval\u2026 what's next?","volume":"60","author":"Pugsley","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0365","series-title":"Principles of safety pharmacology","first-page":"353","article-title":"Inclusion of safety pharmacology endpoints in repeat-dose toxicity studies","volume":"vol. 229","author":"Redfern","year":"2015"},{"key":"10.1016\/j.vascn.2016.06.001_bb0370","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vascn.2005.04.005","article-title":"Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds","volume":"52","author":"Redfern","year":"2005","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0375","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1039\/c3tx20093k","article-title":"Functional assessments in repeat-dose toxicity studies: The art of the possible","volume":"2","author":"Redfern","year":"2013","journal-title":"Toxicology Research"},{"key":"10.1016\/j.vascn.2016.06.001_bb0380","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1529-8027.2010.00262.x","article-title":"The caudal nerves: A model system for experimental neuropathies","volume":"15","author":"Schaumburg","year":"2010","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1016\/j.vascn.2016.06.001_bb0385","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1191\/096032700673027800","article-title":"Lack of peripheral neuropathy in Beagle dogs after 53weeks oral administration of thalidomide capsules","volume":"19","author":"Teo","year":"2000","journal-title":"Human & Experimental Toxicology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0390","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.vascn.2014.02.002","article-title":"Abuse liability assessment in preclinical drug development: Predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models","volume":"70","author":"Teuns","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2016.06.001_bb9100","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.vascn.2016.06.001_bb0395","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vascn.2008.05.007","article-title":"Safety and secondary pharmacology: Successes, threats, challenges and opportunities","volume":"58","author":"Valentin","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.06.001_bb0400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1476-5381.2009.00530.x","article-title":"Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines","volume":"159","author":"Valentin","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0405","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bph.13207","article-title":"Evaluation of drug-induced QT interval prolongation in animal and human studies: A literature review of concordance","volume":"172","author":"Vargas","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0410","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2016.06.001_bb0415","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","article-title":"Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies","volume":"44","author":"Wolf","year":"2008","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.vascn.2016.06.001_bb0420","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000275491","article-title":"Geographic and ethnic variation in Parkinson disease: A population-based study of US Medicare beneficiaries","volume":"34","author":"Wright Willis","year":"2010","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vascn.2016.06.001_bb0425","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/254789","article-title":"Non-invasive evaluation of nerve conduction in small diameter fibers in the rat","volume":"2013","author":"Zotova","year":"2013","journal-title":"Physiology Journal"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871916300570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871916300570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:03:57Z","timestamp":1761005037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871916300570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":86,"alternative-id":["S1056871916300570"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2016.06.001","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety pharmacology investigations on the nervous system: An industry survey","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}